# PureTech Health Receives $200 Million from Sale of Minority Affiliate Shares

- Link: https://www.directorstalkinterviews.com/puretech-health-receives-200-million-from-sale-of-minority-affiliate-shares/412803709
- Published: 2020-01-23T08:17:50+00:00
- Author: Giles Arbor

**PureTech Health plc** (LON: PRTC), a clinical stage biotechnology company dedicated
to discovering, developing and commercialising highly differentiated medicines for
devastating diseases, today announces that it has sold 2.1 million shares of its
affiliate Karuna Therapeutics (NASDAQ: KRTX) for a cash consideration of approximately
$200 million to Goldman Sachs & Co. LLC. PureTech intends to use the proceeds from
the Transaction to fund its operations and growth for the foreseeable future and
to further expand and advance its clinical stage, wholly owned pipeline.

Following the Transaction, PureTech continues to hold 5,295,397 shares of Karuna
common stock, which is equal to 20.4% of Karuna’s outstanding shares, and has a 
right to royalty payments on net sales of any commercialised product covered by 
a license granted by PureTech to Karuna.

> **Daphne Zohar, founder and chief executive officer of PureTech said:**
> “As a founder of Karuna and co-inventor of the KarXT program, we are delighted
> to continue to be a major shareholder of Karuna going forward. With multiple efficacy
> studies validating both xanomeline and KarXT, Karuna is well-positioned to be 
> a major player in the neuropsychiatry field. We are particularly enthusiastic 
> about the potential for patients to have a new and differentiated treatment option
> for schizophrenia and related diseases. This is an area that – despite a large
> market where branded therapies have been blockbuster products – has been lacking
> innovation for decades. We have a high degree of confidence in the team, who have
> an impressive track record, to unlock the full potential of the growth opportunities
> that may be available to them.
> “This sale of a minority of our holdings in Karuna provides us with additional
> cash resources to fund our operational growth, including our rapidly growing wholly
> owned pipeline, for the foreseeable future. We believe that this realisation of
> value provides additional validation of PureTech’s overall business strategy.”

The Transaction constitutes a class 2 transaction for the purposes of the UK Financial
Conduct Authority’s Listing Rules.

**About Karuna**

Karuna is a clinical-stage biopharmaceutical company committed to developing and
delivering first-in-class therapies with the potential to transform the lives of
people with CNS disorders – which remain among the most disabling and potentially
fatal disorders worldwide. Galvanized by the understanding that today’s neuropsychiatric
and pain management patients deserve better, Karuna’s mission is to harness the 
untapped potential of the brain’s complex biology in pursuit of novel therapeutic
pathways that will advance the standard of care. For more information, please visit
karunatx.com.

**About PureTech Health**

PureTech is a clinical stage biotechnology company dedicated to discovering, developing
and commercialising highly differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases, central nervous system
disorders, and inflammatory and immunological diseases, among others. The Company
has created a broad and deep pipeline through the expertise of its experienced research
and development team and its extensive network of scientists, clinicians and industry
leaders. This pipeline, which is being advanced both internally and through PureTech’s
affiliates, is comprised of 23 product candidates and one product that has been 
cleared by the US Food and Drug Administration (FDA). All of the underlying programmes
and platforms that resulted in this pipeline of product candidates were initially
identified or discovered and then advanced by the PureTech team through key validation
points based on the Company’s unique insights into the biology of the brain, immune,
and gut, or BIG, systems and the interface between those systems, referred to as
the BIG Axis.

Share on:
